CureVac Shareholders Face Critical Acquisition Deadline

Acquisition Hinges on Shareholder Approval Threshold

The biotechnology sector is watching closely as BioNTech’s proposed acquisition of CureVac enters its decisive phase. With a November 25 shareholder meeting approaching, investors must determine whether to accept the takeover bid that could reshape the mRNA therapeutics landscape.

BioNTech has established clear parameters for its acquisition proposal, offering approximately $5.46 per CureVac share through American Depositary Shares (ADSs) of its own stock. This values the potential transaction at around $1.25 billion. However, the deal contains a critical contingency: it requires acceptance from at least 80% of CureVac shareholders to proceed. BioNTech has indicated it would only consider lowering this threshold to 75% under exceptional circumstances.